Shilpa Medicare launches Lenvatinib Capsules in India under the brand name Lenshil

The company is already marketing the 4 mg and 10 mg strengths

Wacker Biotech partners with Caeregen Therapeutics on regenerative treatment for vision loss

As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands

USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata

LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12

Aurobindo's subsidiary to withdraw application for EU marketing authorization of two biosimilars

This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA

Natural Capsules announces strategic investment by Somerset Indus Capital Partners

Eugia Pharma signs voluntary license with Medicines Patent Pool to develop generic version of Nilotinib Capsules

The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Venus Remedies receives approval to market meropenm in Spain

The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries

Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler

This product will be manufactured at Lupin's Pithampur facility in India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth